Lupin Manufacturing Solutions Unveils Advanced Oncology Block in Vizag
Lupin Manufacturing Solutions (LMS), a subsidiary of Lupin Limited, has commissioned a new Oncology Block at its Vizag facility in India. The state-of-the-art facility enhances LMS's capabilities in developing and manufacturing High Potent Active Pharmaceutical Ingredients (HPAPIs) for oncology drugs. The block features a 4,270 sq. ft. area, 20 KL reactor capacity, and advanced containment systems. It supports the entire lifecycle of oncology drug development, from preclinical research to commercial manufacturing, with integrated Process Development and Quality Control laboratories. The facility adheres to global regulatory standards and implements stringent safety measures, including isolator-based operations and robust effluent detoxification systems.
*this image is generated using AI for illustrative purposes only.
Lupin Manufacturing Solutions (LMS), a wholly owned subsidiary of Lupin Limited, has announced the commissioning of a state-of-the-art Oncology Block at its Vizag facility in India. This strategic move significantly enhances LMS's capabilities in the development and manufacturing of High Potent Active Pharmaceutical Ingredients (HPAPIs) for oncology drugs.
Key Features of the New Oncology Block
The new facility boasts impressive specifications:
| Feature | Details |
|---|---|
| Total Area | 4,270.00 |
| Reactor Capacity | 20.00 |
| Containment Systems | 20.00 |
| Exposure Levels | 0.05 |
| Batch Range | 1.00-35.00 |
| Environmental Controls | 25.00, 45.00 |
Enhanced Capabilities
The Oncology Block is designed to support the entire lifecycle of oncology drug development, from preclinical research to commercial manufacturing. It integrates a Process Development Laboratory with a dedicated Quality Control laboratory, enabling:
- Early-stage route scouting
- Analytical development
- Process optimization
- Validation
This integrated approach allows for seamless transition from lab-scale synthesis to full-scale commercial manufacturing.
Advanced Safety and Compliance
LMS has implemented stringent safety measures and compliance standards in the new facility:
- Isolator-based operations at every process step
- Integrated SCADA systems
- Robust effluent detoxification system
- Adherence to global regulatory standards and Lupin's quality protocols
Strategic Importance
Dr. Abdelaziz Toumi, Chief Executive Officer of Lupin Manufacturing Solutions, emphasized the strategic importance of this new facility: "This state-of-the-art facility enhances our capacity to produce high-quality APIs and develop impactful therapies that benefit patients globally. This marks a major milestone in LMS's evolution into a dedicated and trusted CDMO partner for oncology innovators."
About Lupin Manufacturing Solutions
LMS, a 100% subsidiary of Lupin Limited, operates as a manufacturer of active pharmaceutical ingredients and a global contract development and manufacturing organization (CDMO). The company offers integrated solutions across drug substances, complex chemistry, drug products, and advanced modalities, including Antibody-Drug Conjugates (ADCs) and peptides.
Conclusion
The inauguration of this Oncology Block represents a significant step forward for Lupin Manufacturing Solutions in the field of oncology research and manufacturing. By combining Lupin's scientific legacy with advanced containment facilities and regulatory excellence, LMS aims to accelerate the development of oncology treatments from concept to commercialization, potentially bringing hope to patients worldwide more quickly and efficiently.
This article is based on a press release dated November 12, 2025, from Lupin Limited.
Historical Stock Returns for Lupin
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.12% | +4.23% | +6.09% | -0.78% | +1.96% | +126.79% |
17
